Baidu
map

Eur Heart J:多学科讨论——他汀使用对VTE复发具有获益!

2017-06-12 吴刚 环球医学

2017年5月,发表在《Eur Heart J》的一项观察性队列研究的系统评价和Meta分析评估了他汀的使用和VTE复发风险之间的相关性。

已经建议,他汀在静脉血栓栓塞(VTE)(包括深静脉血栓(DVT)和肺栓塞(PE))的二级预防中起到潜在作用,但是证据并不一致。2017年5月,发表在《Eur Heart J》的一项观察性队列研究的系统评价和Meta分析评估了他汀的使用和VTE复发风险之间的相关性。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——

在该项研究中,从Medline、Embase、科学网以及参考文献的人工检索中鉴别出所有报道了他汀使用和VTE复发结局之间相关性的相关研究,截止日期为2017年1月。使用随机效应模型汇总研究特异性相对风险(RR)及其95%可信区间。符合要求的8项研究纳入到汇总分析中,其中包括103576名参与者和13168例VTE复发结局。7项研究的汇总分析中,当将他汀使用与不使用相比较时,VTE复发的RR为0.73(0.68~0.79)。没有证据表明,有影响力的研究间具有异质性(I2,0%;0~71%;P=0.93)。当比较他汀使用和不使用时,PE复发(3项研究)和DVT复发(2项研究)的RR分别为0.75(0.58~0.96)和0.66(0.60~0.71)。

现有的观察性队列研究中的证据表明,他汀使用对VTE复发具有获益影响。需要良好设计的干预性研究来证实这些结果。

多学科讨论记实:

VTE 是死亡和残疾的主要原因。据估计,全世界每年约有1000万例病例,这是医院相关死亡的最可预防的原因之一。

他汀因其“多效性”在临床广泛使用,除了降胆固醇外,他汀还有抗炎、稳定粥样斑块、改善血管内皮、保护神经、影响血栓形成等功能。

2017年2月,发表在《Lancet Haematol》的一项系统评价和荟萃分析评价了他汀与首次VTE事件相关性的程度。结果表明,他汀类药物对VTE存在获益。而上述观察性队列研究显示,他汀使用对VTE复发具有获益影响。这些研究表明,他汀类可能在 VTE的一级和二级预防中起着潜在的作用,而这一发现可能会导致新的指导方针和扩大治疗的使用。

原始出处:

Kunutsor SK, Seidu S and Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J. 2017 May 21;38(20):1608-1612. doi: 10.1093/eurheartj/ehx107.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1356324, encodeId=bf391356324ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439838, encodeId=647f1439838e9, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562558, encodeId=0250156255858, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210292, encodeId=fd00210292f5, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 13 18:49:30 CST 2017, time=2017-06-13, status=1, ipAttribution=)]
    2017-06-14 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1356324, encodeId=bf391356324ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439838, encodeId=647f1439838e9, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562558, encodeId=0250156255858, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210292, encodeId=fd00210292f5, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 13 18:49:30 CST 2017, time=2017-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1356324, encodeId=bf391356324ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439838, encodeId=647f1439838e9, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562558, encodeId=0250156255858, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210292, encodeId=fd00210292f5, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 13 18:49:30 CST 2017, time=2017-06-13, status=1, ipAttribution=)]
    2017-06-14 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1356324, encodeId=bf391356324ad, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439838, encodeId=647f1439838e9, content=<a href='/topic/show?id=35904318480' target=_blank style='color:#2F92EE;'>#多学科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43184, encryptionId=35904318480, topicName=多学科)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562558, encodeId=0250156255858, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jun 14 07:37:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210292, encodeId=fd00210292f5, content=不错的,学习了!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Tue Jun 13 18:49:30 CST 2017, time=2017-06-13, status=1, ipAttribution=)]
    2017-06-13 虈亣靌

    不错的,学习了!谢谢分享!

    0

相关资讯

拜耳/强生拜瑞妥® 预防静脉血栓栓塞

一项最新3期临床试验显示和阿司匹林相比,拜耳和杨森的新型口服抗凝剂(NOAC)拜瑞妥 (利伐沙班片)可以更有效地防止复发性血栓,同时不会增加出血风险。

J Thromb Haemost:初始肿瘤分期对静脉血栓栓塞的发病率有何影响?

由此可见,在诊断时分期更晚的癌症患者发生VTE的风险较高,但这种相关性的强度随着癌症类型的变化有很大的差别。

近期静脉血栓栓塞指南共识及研究汇总

静脉血栓栓塞症(VTE)为癌症患者的主要并发症,发生率为4%~20%,并且为导致死亡的原因。VTE包括深静脉血栓形成(DVT)及肺栓塞(PE)。 癌症患者DVT的风险增加数倍,住院的癌症患者及正接受药物治疗的患者发生DVT的风险更大。本文梅斯医学小编就近期静脉血栓栓塞研究进行汇总,分享于大家。【1】Am J Kidney Dis:肾脏疾病与静脉血栓栓塞风险之间啥关系? 近日,肾脏病领

Haematologica:癌症患者静脉血栓栓塞风险预测评分比较!

总之,在癌症患者中静脉血栓栓塞的预测评分表现不佳。Vienna CATS和PROTECHT评分在区分低风险和高风险患者之间效果比较好,但考虑用于临床实践前仍需要进一步改进。

Ann Surg:减肥术后会导致静脉血栓么?

目的:静脉血栓栓塞(VTE)是减肥手术(BS)后的主要关注点,特别是在院后放电(PHD)期间要被重点关注。但目前没有大规模的研究评估PHD化学预防的临床价值。本研究的目的是评估在BS后的发病率,危险因素以及PHD化学预防对VTE的影响。

Intens Care Med:重症颅脑损伤患者发生静脉血栓栓塞事件的风险如何?

由此可见,尽管机械和药物预防,在ICU治疗的TBI患者中每五例患者就有1例患者发生VTE。年龄越大、体重越重以及TBI月严重,患者发生VTE的风险会增加。VTE的发生与死亡率增加无关。

Baidu
map
Baidu
map
Baidu
map